Haiping Dai

Soochow University — China

Medicine · Health Sciences

21h-index1.9kcitations168works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(60), CAR-T cell therapy research(60), Acute Lymphoblastic Leukemia research(48), Chronic Myeloid Leukemia Treatments(36), Histone Deacetylase Inhibitors Research(13)

Publications168 total

Coexistence of <i>BCR::ABL1</i> with <i>IKZF1::ETV6</i> fusion in an adult patient with acute B-lymphoblastic leukemia
Leukemia & lymphoma/Leukemia and lymphoma·2026
Donor-derived and patient-derived IL-6 knock-down CAR T-19 exhibit similar efficacy and safety in treating relapsed B-cell acute lymphoblastic leukemia patients after allo-HSCT
Cytotherapy·2026
Regulated expression of miR-99a and miR-100 relates clinical and prognostic parameters of acute myeloid leukemia
Hematology·2025Open Access
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial
The Lancet Haematology·2025
Integrative clinical and molecular characterization of an acute promyelocytic leukemia-like subgroup with high early death risk in newly diagnosed acute myeloid leukemia: a multicenter study
Haematologica·2025Open Access
A phase 2 trial of a “sandwich” strategy: Sequential CD22/CD19 chimeric antigen receptor T‐cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome–negative B‐cell acute lymphoblastic leukemia
Cancer·2025Open Access
Venetoclax, cladribine plus low-dose cytarabine for relapsed/refractory Acute Myeloid Leukemia: A multicenter, randomized phase II Study
Blood·2025Open Access
Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of Zefamenib combined with chemotherapy or targeted Agents in patients with Acute Myeloid Leukemia
Blood·2025
Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study
Blood·2025Open Access
Enhanced homing and infiltration capabilities of CI9 cells improve treatment efficacy for T-cell acute lymphoblastic leukemia with extramedullary involvement
Blood·2025
Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia
Blood·2025Open Access
Efficacy and Safety of Electroacupuncture for Postherpetic Neuralgia and Biomarker Evaluation: A Study Protocol for a Multicenter, Randomized Trial
Journal of Pain Research·2025· 1 citedOpen Access
IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial
Blood Cancer Journal·2025Open Access
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT
Clinical Epigenetics·2025Open Access
Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis
Leukemia & lymphoma/Leukemia and lymphoma·2025
[A Study of Flow Sorting Lymphocyte Subsets to Detect Epstein-Barr Virus Reactivation in Patients with Hematological Malignancies].
PubMed·2025
Developing a Framework of Entrustable Professional Activities for Residency Training in Hematology
Advances in Medical Education and Practice·2025Open Access
Adult AML with NUP98 rearrangements should be stratified into adverse-risk group
Blood Cancer Journal·2025· 1 citedOpen Access
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial
Journal of Hematology & Oncology·2025· 13 citedOpen Access
Comparative Analysis of Treatment Effects of Different Materials on Thin Oil Films
Materials·2025Open Access
page 1 of 9Next →

Frequent Co-authors

Xiaowen Tang(30), Depei Wu(27), Jia Yin(17), Xiaming Zhu(16), Shengli Xue(15), Qingya Cui(12), Liqing Kang(12), Suning Chen(10), Changju Qu(9), Hongjie Shen(9), Lei Yu(8), Mingqing Zhu(7), Wei Cui(7), Aining Sun(7), Depei Wu(7), Chengcheng Fu(6), Xinyue Zhang(6), Huiying Qiu(6), Zheng Li(5), Yang Xu(5)